DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable Secretome to initiate clinical trials for its lead asset, STM-01, and further advance its innovative pipeline..

达拉斯--（商业新闻短讯）--生物技术公司Secretome Therapeutics今天宣布，成功完成了一轮2040万美元的融资。Secretome Therapeutics是一家推进新生儿心脏祖细胞（NCPC）治疗的生物技术公司。这笔资金将使Secretome能够启动其主要资产STM-01的临床试验，并进一步推进其创新渠道。。

Key Upcoming Milestones

即将到来的关键里程碑

The capital raised in this round will support operations through mid-2026 and fund key initiatives, including:

本轮融资将支持运营直至2026年年中，并为关键举措提供资金，包括：

Clinical Trials: Launching two Phase 1 trials of STM-01 in HFpEF (heart failure with preserved ejection fraction) and DCM (dilated cardiomyopathy), with proof-of-concept data expected in Q3 2025.

临床试验：在HFpEF（射血分数保留的心力衰竭）和DCM（扩张型心肌病）中启动STM-01的两项1期临床试验，预计2025年第3季度将有概念验证数据。

Manufacturing Scale-Up: Transitioning STM-01 manufacturing to 3-dimensional bioreactor technology.

制造规模扩大：将STM-01制造转变为三维生物反应器技术。

Pipeline Development: Advancing STM-21 and other preclinical programs to address inflammatory conditions.

管道开发：推进STM-21和其他临床前计划以解决炎症状况。

Regulatory Engagement: Defining the regulatory pathway for STM-01 in orphan indications.

监管参与：定义孤儿适应症中STM-01的监管途径。

Intellectual Property: Submitting patents on next-generation cell and secretome products following the issuance of composition patents for STM-01 and STM-21.

知识产权：在STM-01和STM-21的组成专利发布后，提交下一代细胞和分泌蛋白产品的专利。

Advancing STM-01 into Clinical Development

将STM-01推进临床开发

Secretome plans to initiate two multiple-ascending dose Phase 1 trials of STM-01 by the end of 2024:

The first trial, led by Dr. Sanjiv Shah, founder of the world's first dedicated clinical program for HFpEF at Northwestern University Feinberg School of Medicine, will evaluate STM-01 in patients with HFpEF.

西北大学范伯格医学院（Northwestern University Feinberg School of Medicine）全球首个HFpEF专用临床项目的创始人桑吉夫·沙阿（Sanjiv Shah）博士领导的第一项试验将评估STM-01在HFpEF患者中的作用。

The second trial, an investigator-sponsored study led by Dr. Arshed Quyyumi, Co-Director of Emory University’s Clinical Cardiovascular Research Institute, will study STM-01 in patients with non-ischemic DCM.

第二项试验是由埃默里大学临床心血管研究所联合主任Arshed Quyyumi博士领导的一项研究者赞助的研究，将研究非缺血性扩张型心肌病患者的STM-01。

“We are grateful to have investors who share our vision and whose support enables Secretome to become a world-class drug development company,” said Vinny Jindal, Co-Founder, President, and CEO of Secretome Therapeutics. “Stem cells have shown extraordinary therapeutic potential, but challenges that include manufacturing inconsistencies have limited their broader application.

Secretome Therapeutics联合创始人、总裁兼首席执行官维尼·金达尔（VinnyJindal）表示：“我们感谢与我们有共同愿景的投资者，他们的支持使Secretome成为世界一流的药物开发公司。“干细胞显示出非凡的治疗潜力，但包括制造不一致在内的挑战限制了其更广泛的应用。

Our neonatal CPC platform delivers unmatched consistency and potency, positioning Secretome to become a clear leader in this emerging area of medicine.”.

我们的新生儿CPC平台提供了无与伦比的一致性和效力，使Secretome成为这一新兴医学领域的明确领导者。”。

About Secretome Therapeutics

关于分泌蛋白治疗学

Secretome Therapeutics is developing therapies derived from neonatal cardiac progenitor cells (nCPCs) to address life-threatening cardiovascular diseases and conditions driven by inflammation. Our lead drug is STM-01, a first-in-class cellular therapy designed to reduce inflammation, inhibit fibrosis, and support tissue repair in DCM and HFpEF.

Secretome Therapeutics正在开发源自新生儿心脏祖细胞（NCPC）的疗法，以解决威胁生命的心血管疾病和由炎症驱动的疾病。我们的主要药物是STM-01，这是一种一流的细胞疗法，旨在减轻DCM和HFpEF的炎症，抑制纤维化并支持组织修复。

We are also developing STM-21, a secretome-based therapeutic in preclinical development for inflammatory conditions, including skin wounds and co-morbidities of diabetes..

我们还在开发STM-21，这是一种基于分泌组的治疗炎症疾病的临床前开发，包括皮肤伤口和糖尿病合并症。。